Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral Ltd, a Mumbai-based pharmaceutical company, reported strong Q4 FY25 results with revenue from operations rising 41.3% year-on-year to Rs 181.8 million. Profit after tax jumped 74.4% YoY to Rs 21.9 million, and EPS for the quarter stood at Rs 1.84. For the full year FY25, revenue grew 28.8% to Rs 701.0 million, EBITDA margin improved by 41 basis points to 16.5%, and PAT grew 31.4% to Rs 81.0 million, with EPS at Rs 6.89 versus Rs 5.28 in FY24. The Injectables segment led with Rs 411.8 million in revenue, while the Oral segment surged 62.9% and Nutraceuticals posted a 564% jump. Exports contributed 27.5% of revenue, with core international markets (CIS, Middle East & Africa, Latin America) accounting for 81.5% of FY25 revenue.
Strong double-digit revenue and profit growth in both Q4 and full-year FY25, along with margin expansion, signals healthy operational momentum. However, gross margin compression (down from 61.9% to 50.7% in Q4) and the Q4 EBITDA margin dip despite revenue surge may temper near-term enthusiasm, though the overall annual results remain positive for shareholders.